Pharmaco - Today Stories

Recent studies suggest current approach to current cardiovascular risk assessment is inadequate / A more personalized approach offers new opportunities for positive intervention / Affordable, accessible tools like ultrasound increase access to assessing cardiovascular risk Basel, Switzerland, February 18, 2025 – With the recent 125th anniversary of aspirin’s discovery, new research is shedding light on innovative approaches to cardiovascular health that can increase access to cardiovascular disease prevention through more precise and individualized care. A series of recent studies emphasize the importance of viewing cardiovascular risk as a continuum and utilizing affordable and easily available tools like carotid ultrasound to better assess individual patient risk, ther…

The company, with two endocrinology products approved by both the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), is developing additional endocrinology and oncology therapies, and has formed strategic partnerships in other indications and markets. The development of these drugs is based on the innovative TransCon® technology platform, which combines the efficacy of the parent drug, whose biology is known, with the benefits of prodrug and a sustained release mechanisms. London, United Kingdom, February 6th 2024 – Ascendis Pharma UK, a subsidiary of the global biopharmaceutical company with a portfolio of products and product candidates specialising in rare endocrine diseases, has opened a UK office and appointed a senior management team led by UK Genera…

The Apex is the first phase of a one million sq ft of purpose-built life sciences space in King’s Cross’ Knowledge Quarter The London BioScience Innovation Centre (LBIC) signed a lease on 39,000 sq ft or c. 35% of the space in the building The Francis Crick Institute is collaborating on 52,000 sq ft of space in the building 11 February 2025, London – Reef Group (“Reef”), the leading property development and investment specialist, and BlackRock Real Estate, have completed The Apex, the first laboratory building at TRIBECA, London’s largest purpose-built life science campus. The Apex is the first phase of the development and comprises over 110,000 sq ft of laboratory and office space, set over six floors. As a purpose-built life sciences campus, The Apex and subsequent phases of TRIBECA ha…

[Dublin, 10th February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global markets. The new facilities, located in Raleigh, USA, Lelystad, Netherlands, and Dublin, Ireland, reflect Uniphar’s commitment to enhancing its logistics and distribution capabilities within global pharmaceutical and healthcare sectors. With 57 years’ industry experience, Uniphar’s new facilities position the company to support pharmaceutical and biotech companies more effectively, offering comprehensive solutions that cover the entire product lifecycle. The new locations aim to ensure the timely delivery of critical therapies to patients worldwide, whil…

RESEARCH TRIANGLE PARK, N.C. – February 4, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World’s Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on four key attributes — innovation, global competitiveness, people management and use of corporate assets. “We are deeply honored to be recognized for the fourth year in a row as number one on the World’s Most Admired Companies list for our category, and to be named to the list for the eighth consecuti…

BURLINGTON, N.C. (January 29, 2025) – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's 2025 list of the World’s Most Admired Companies,™ a recognition of the most respected and reputable companies globally. “We are proud to once again be named to FORTUNE’s World's Most Admired Companies list,” said Adam Schechter, chairman and CEO of Labcorp. “This honor reflects the continuous hard work and commitment of our employees to help us advance our mission to improve health and improve lives around the world.”   Labcorp ranked second in the “Healthcare: Pharmacy and Other Services” category, up from fourth place in 2024, scoring top marks in quality of management, financial soundness, long-term investment and…

Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker, and will become a member of the enlarged Corporate Executive Committee starting 10 February 2025.  She will be based at Genentech in South San Francisco. In this new role, she will take over the worldwide responsibility for the Informatics function for the Roche Group from Alan Hippe, who currently has the dual role of Chief Financial Officer (CFO) and Chief Informatics Officer (CIO).  With our ambitions to transform our business with digital solutions and through enterprise-wide use of artificial intelligence, this is the right moment to split the two roles and ensure dedicated foc…

Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis (tadalafil) from a prescription to an over-the-counter medicine. This decision allows for the initiation of the AUT and makes Cialis the first PDE-5 inhibitor to achieve this milestone. AUTs evaluate the use of the medicine under real-world conditions to identify any issues that have not previously been identified and to confirm that consumers can self-diagnose and treat themselves appropriately without the help of a healthcare provider. Julie Van OngevallePresident and CEO, Opella“We are pleased that the FDA has completed the…

The data uncover broad optimism as well as stark regional disparities and cultural obstacles in the West that must be addressed to increase public acceptance of breakthrough innovations / More than 13,000 people surveyed in 13 countries representing every continent except Antarctica / The survey explored the public’s perceptions of cell and gene therapies, AI in medicine, new genomic techniques (NGTs) in agriculture, and cultivated meat Berlin, Germany, January 20, 2025 – As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public sentiment towards transformative technology. The field work was con…

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers GSK to pay up to $1.15 billion GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based reg…

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases. “Studies on the human proteome are having a profound impact on our customers’ fundamental understanding of disease and the advancement of life sciences research,” said Marc N. C…

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular disease Expanded collaboration includes near-term payments totalling up to 190 million US dollars, while Valo is eligible to receive milestone payments of approximately 4.6 billion dollars, plus R&D funding and potential royalty payments Bagsværd, Denmark and Lexington, Massachusetts, US, 8 January 2025 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (…

Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro’s Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FRα expressing cancers.  For the first time, the cross-functional teams were able to scale up Sutro’s cell-free protein synthesis platform from a small-scale Good Manufacturing Practice (GMP) production to a large-scale GMP production marking an industry milestone. All batches of luvelta manufactured in 4,500 L at Boehringer’s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for the…

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) --  Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari’s innovative product portfolio is highly complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Each year, VTE impacts u…

Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital, with additional investment from founding investor Medicxi Strengthens its leadership team with the appointments of industry veterans Rick Anderson as SVP Finance, Spencer Fisk as Chief Technical and Quality Officer, and Ling Zeng as General Counsel and EVP of Execution IND-enabling studies underway for first-in-class PD1/VEGFR2 bifunctional antibody [19 December 2024]: [London, UK/ Boston, US]: Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for mul…

Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US). The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here. “We are very pleased with the completion of the acquisition. The three sites will expand our manufacturing capacity at scale and speed, while complementing our ongoing significant internal supply chain expansions. The acquisition will enable us to reach significantly more people living with serious chronic dise…

Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board will commence a formal search process to identify a new CEO, which is anticipated to conclude within…

Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site.   The new site will feature a state-of-the-art finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as haemophilia, both now and in the future.    "The facility will utilise advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” says Henrik Wulff, executive vice p…

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilities NORTH CHICAGO, Ill., Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie. Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the centr…

CLOSE Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 lives Nebraska's win was announced at the Discover Big Ten Football Championship Game where the university received $1 million from global healthcare company Abbott to advance student and community health The competition, which will be back next fall, aims to help combat the greatest need for blood in a generation, while also helping create new lifelong blood donors ABBOTT PARK, Ill., and INDIANAPOLIS, Dec. 7, 2024 /PRNewswire/ -- This college football season, Abbott (NYSE: ABT) and the Big Ten put fandom and the hearts of Big Ten communities to the test with their inaugural blood…